Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 13 studies | 28% ± 10% | |
peripheral blood | 13 studies | 24% ± 8% | |
kidney | 7 studies | 21% ± 7% | |
liver | 7 studies | 35% ± 23% | |
brain | 7 studies | 35% ± 14% | |
intestine | 6 studies | 28% ± 11% | |
eye | 6 studies | 26% ± 9% | |
bone marrow | 5 studies | 22% ± 5% | |
pancreas | 4 studies | 29% ± 5% | |
uterus | 4 studies | 37% ± 16% | |
lymph node | 4 studies | 23% ± 4% | |
placenta | 3 studies | 27% ± 1% | |
breast | 3 studies | 25% ± 7% | |
adipose | 3 studies | 19% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
bladder | 100% | 3894.67 | 21 / 21 | 100% | 63.18 | 504 / 504 |
esophagus | 100% | 4254.19 | 1445 / 1445 | 100% | 76.58 | 183 / 183 |
ovary | 100% | 4445.43 | 180 / 180 | 100% | 60.24 | 430 / 430 |
prostate | 100% | 3547.58 | 245 / 245 | 100% | 67.36 | 502 / 502 |
stomach | 100% | 2929.82 | 359 / 359 | 100% | 63.53 | 286 / 286 |
uterus | 100% | 4335.13 | 170 / 170 | 100% | 70.97 | 459 / 459 |
breast | 100% | 4197.15 | 459 / 459 | 100% | 68.89 | 1117 / 1118 |
brain | 100% | 3152.06 | 2639 / 2642 | 100% | 84.81 | 705 / 705 |
lung | 100% | 3665.51 | 577 / 578 | 100% | 72.14 | 1154 / 1155 |
intestine | 100% | 4069.77 | 966 / 966 | 100% | 66.07 | 525 / 527 |
pancreas | 99% | 2909.40 | 326 / 328 | 100% | 49.39 | 178 / 178 |
thymus | 100% | 3554.03 | 653 / 653 | 99% | 62.61 | 601 / 605 |
liver | 100% | 2933.04 | 226 / 226 | 99% | 41.89 | 402 / 406 |
adrenal gland | 100% | 5292.90 | 258 / 258 | 99% | 62.35 | 227 / 230 |
kidney | 100% | 3204.45 | 89 / 89 | 98% | 44.96 | 880 / 901 |
skin | 100% | 5839.86 | 1809 / 1809 | 97% | 64.87 | 458 / 472 |
adipose | 100% | 4366.41 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 4838.83 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 91.43 | 29 / 29 |
muscle | 100% | 4947.48 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 3184.34 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 69.70 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 47.36 | 1 / 1 |
heart | 97% | 3088.58 | 832 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 95% | 41.78 | 76 / 80 |
peripheral blood | 58% | 2201.40 | 543 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0016485 | Biological process | protein processing |
GO_0031365 | Biological process | N-terminal protein amino acid modification |
GO_0018206 | Biological process | peptidyl-methionine modification |
GO_0005829 | Cellular component | cytosol |
GO_0005886 | Cellular component | plasma membrane |
GO_0005737 | Cellular component | cytoplasm |
GO_0004239 | Molecular function | initiator methionyl aminopeptidase activity |
GO_0008235 | Molecular function | metalloexopeptidase activity |
GO_0005515 | Molecular function | protein binding |
GO_0070006 | Molecular function | metalloaminopeptidase activity |
GO_0046872 | Molecular function | metal ion binding |
GO_0004177 | Molecular function | aminopeptidase activity |
GO_0003723 | Molecular function | RNA binding |
Gene name | METAP2 |
Protein name | Methionine aminopeptidase 2 (MAP 2) (MetAP 2) (EC 3.4.11.18) (Initiation factor 2-associated 67 kDa glycoprotein) (p67) (p67eIF2) (Peptidase M) Methionyl aminopeptidase 2 Methionine aminopeptidase 2 (MAP 2) (MetAP 2) (EC 3.4.11.18) (Initiation factor 2-associated 67 kDa glycoprotein) (Peptidase M) (p67) (p67eIF2) Alternative protein METAP2 |
Synonyms | hCG_2015111 MNPEP P67EIF2 |
Description | FUNCTION: Cotranslationally removes the N-terminal methionine from nascent proteins. The N-terminal methionine is often cleaved when the second residue in the primary sequence is small and uncharged (Met-Ala-, Cys, Gly, Pro, Ser, Thr, or Val). The catalytic activity of human METAP2 toward Met-Val peptides is consistently two orders of magnitude higher than that of METAP1, suggesting that it is responsible for processing proteins containing N-terminal Met-Val and Met-Thr sequences in vivo.; FUNCTION: Protects eukaryotic initiation factor EIF2S1 from translation-inhibiting phosphorylation by inhibitory kinases such as EIF2AK2/PKR and EIF2AK1/HCR. Plays a critical role in the regulation of protein synthesis. FUNCTION: Cotranslationally removes the N-terminal methionine from nascent proteins. The N-terminal methionine is often cleaved when the second residue in the primary sequence is small and uncharged (Met-Ala-, Cys, Gly, Pro, Ser, Thr, or Val). .; FUNCTION: Protects eukaryotic initiation factor EIF2S1 from translation-inhibiting phosphorylation by inhibitory kinases such as EIF2AK2/PKR and EIF2AK1/HCR. Plays a critical role in the regulation of protein synthesis. . FUNCTION: Cotranslationally removes the N-terminal methionine from nascent proteins. The N-terminal methionine is often cleaved when the second residue in the primary sequence is small and uncharged (Met-Ala-, Cys, Gly, Pro, Ser, Thr, or Val). .; FUNCTION: Protects eukaryotic initiation factor EIF2S1 from translation-inhibiting phosphorylation by inhibitory kinases such as EIF2AK2/PKR and EIF2AK1/HCR. Plays a critical role in the regulation of protein synthesis. . FUNCTION: Cotranslationally removes the N-terminal methionine from nascent proteins. The N-terminal methionine is often cleaved when the second residue in the primary sequence is small and uncharged (Met-Ala-, Cys, Gly, Pro, Ser, Thr, or Val). .; FUNCTION: Protects eukaryotic initiation factor EIF2S1 from translation-inhibiting phosphorylation by inhibitory kinases such as EIF2AK2/PKR and EIF2AK1/HCR. Plays a critical role in the regulation of protein synthesis. . |
Accessions | L0R5B9 ENST00000549502.5 ENST00000546753.5 [P50579-3] ENST00000551840.5 F8VRR3 ENST00000535095.5 F8VY03 P50579 ENST00000323666.10 [P50579-1] A0A140VJE3 ENST00000549808.1 F8VSC4 ENST00000553151.5 G3V1U3 ENST00000550777.5 F8VQZ7 F8VZX9 ENST00000261220.13 [P50579-2] |